1-3 of 3
Yvan Jamilloux
Close
Sort by
Journal Articles

Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study

Clinical Trials & Observations
Maël Heiblig, Marcela A. Ferrada, Matthew T. Koster, Thomas Barba, Mathieu Gerfaud-Valentin, Arsène Mékinian, Henrique Coelho, Gaelle Fossard, Fiorenza Barraco, Lionel Galicier, Boris Bienvenu, Pierre Hirsch, Guillaume Vial, Anne Blandine Boutin, Joris Galland, Guillaume Le Guenno, Adrien Bigot, Kenneth J. Warrington, Tanaz A. Kermani, Peter C. Grayson, Bhavisha A. Patel, David B. Beck, Yvan Jamilloux, Pierre Fenaux, Pierre Sujobert
Journal: Blood
Blood (2022) 140 (8): 927–931.
https://doi.org/10.1182/blood.2022016642
Published: 2022
Includes: Supplemental data
Journal Articles

Clinical Efficacy of JAK Inhibitors in Patients with Vexas Syndrome: A Multicenter Retrospective Study

Maël Heiblig, Marcela A Ferrada, Mathieu Gerfaud-Valentin, Thomas Barba, Arsène Mékinian, Matthew Koster, Henrique Coelho, Gaelle Fossard, Fiorenza Barraco, Lionel Galicier, Boris Bienvenu, Pierre Hirsch, Guillaume Vial, Anne Blandine Boutin, Guillaume Le guenno, Adrien Bigot, Kenneth Warrington, Tanaz Kermani, Yvan Jamilloux, Peter C Grayson, Bhavisha A. Patel, David B. Beck, Pierre Fenaux, Pierre Sujobert
Journal: Blood
Blood (2021) 138 (Supplement 1): 2608.
https://doi.org/10.1182/blood-2021-150394
Published: 2021
Journal Articles

Therapeutic options in VEXAS syndrome: insights from a retrospective series

Clinical Trials & Observations
Estelle Bourbon, Maël Heiblig, Mathieu Gerfaud Valentin, Thomas Barba, Cécile-Audrey Durel, Jean Christophe Lega, Fiorenza Barraco, Pascal Sève, Yvan Jamilloux, Pierre Sujobert
Journal: Blood
Blood (2021) 137 (26): 3682–3684.
https://doi.org/10.1182/blood.2020010177
Published: 2021
Includes: Supplemental data